Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 17/20 | 0.60 |
| ▸ | GLP1R | P43220 | 1/20 | 0.57 |
| ▸ | GCGR | P47871 | 1/20 | 0.57 |
| ▸ | GIPR | P48546 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20997936 | 1.00 | IL23R (0.60) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL20997919 | 1.00 | IL23R (0.60) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL20992994 | 0.98 | IL23R (0.58) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL16692892 | 0.92 | IL23R (0.61) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL16692898 | 0.92 | IL23R (0.61) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL24172454 | 0.92 | IL23R (0.61) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL19731206 | 0.92 | IL23R (0.61) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL19731216 | 0.92 | IL23R (0.61) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL16692899 | 0.92 | IL23R (0.61) | IL23RGLP1RGCGRGIPR | |
| SCHEMBL19731215 | 0.91 | GLP1R (0.61) | IL23RGLP1RGCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
| US-20190144501-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2019-05-16 | — | — | US | disclosed |
| US-20170362302-A1 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer | UNIVERSITE PARIS DIDEROT- PARIS 7 (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20160039908-A1 | Method and Pharmaceutical Composition for use in the Treatment of Cancer | INST NAT SANTE RECH MED (FR) | 2016-02-11 | — | — | US | disclosed |
| US-9198949-B2 | Method and pharmaceutical composition for use in the treatment of cancer | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2015-12-01 | — | — | US | disclosed |
| US-20150126456-A1 | Method and Pharmaceutical Composition for use in the Treatment of Cancer | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126456-A1 | Method and Pharmaceutical Composition for use in the Treatment of Cancer | KLKB1, KLK5, KLK1 | IL23R 856/4885GLP1R 469/4885GCGR 1041/4885 |
| US-20190144501-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | IL23R 704/4885GLP1R 785/4885GCGR 1852/4885 |
| US-20160039908-A1 | Method and Pharmaceutical Composition for use in the Treatment of Cancer | KLKB1, KLK5, KLK1 | IL23R 856/4885GLP1R 469/4885GCGR 1041/4885 |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | IL23R 581/4885GLP1R 1060/4885GCGR 1973/4885 |
| US-20170362302-A1 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer | KLKB1, KLK5, KLK1 | IL23R 856/4885GLP1R 469/4885GCGR 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.